Regeneron Pharmaceuticals Inc
Market cap $68.8B
$656.01
REGN
$656.01
+0.63% today
Buy with €1M virtual cash · No real money
Regeneron Pharmaceuticals Inc (REGN) is a publicly traded company listed on the XNAS. As of July 27, 2026, Invest's signal rates REGN a Hold, with the stock up 15% over the past year. You can practice trading REGN risk-free with €1,000,000 in virtual cash.
Key stats
As of July 27, 2026
Market Cap
$68.8B
Volume
708K
52-wk High
$821.11
52-wk Low
$541.00
Day High
$667.50
Day Low
$654.05
P/E (TTM)
15.98
Revenue (TTM)
$14.9B
EPS (TTM)
$41.05
Performance
1M
+5.2%
6M
-13.2%
1Y
+14.6%
Invest signal · REGN
HoldAlgorithmic signal from price trend, valuation, and fundamentals — educational only, not financial advice.
REGN overview
AI overviewRevenue & EPS — last 8 quarters
QoQ rev -7.2%Revenue
$4BEPS (diluted)
$6.75 per shareLatest REGN news
Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial’s Protocol and Ultimate Failure - HBSS
GlobeNewswire Inc. · 2d ago
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
GlobeNewswire Inc. · 6d ago
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
GlobeNewswire Inc. · Jul 19
Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes
GlobeNewswire Inc. · Jul 17
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider
GlobeNewswire Inc. · Jul 15
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Employees
15,410
30-Day Win Rate · REGN
12 days
11 days
Last 23 sessions
How to practice trading REGN
- 1
Use the REGN buy panel above
Set a quantity and hit Buy at the real market price — right here, nothing to download.
- 2
Trade with €1,000,000 virtual cash
You get a million in virtual money instantly to invest, risk-free.
- 3
Create a free account to save it
Sign up in seconds to keep your portfolio and track its performance.
- 4
Track and compete
Watch your portfolio grow and climb the global leaderboard — or start a private league.
- 5
Prefer mobile? Get the iOS app
Invest is also free on the App Store, synced with your web account.
Top REGN traders on Invest
Full leaderboardFrequently asked questions
Is REGN a good stock to buy right now?
As of July 27, 2026, Invest's signal rates REGN a Hold, based on its price trend, valuation, and fundamentals (P/E around 16.0), with the stock up 15% over the past year. This is an educational signal, not financial advice — the best way to test the thesis is to practice trading REGN risk-free first.
What is Regeneron Pharmaceuticals Inc's (REGN) market cap?
Regeneron Pharmaceuticals Inc has a market capitalization of approximately $68.8B, on trailing-twelve-month revenue of about $14.9B.
How has REGN stock performed?
REGN is up 15% over the past year and down 13% over six months. Its 52-week range runs roughly from $541.00 to $821.11. Past performance doesn't predict future results.
How can I practice trading REGN for free?
On Invest you get €1,000,000 in virtual cash and can buy REGN at real market prices right in your browser — no download and no real money at risk. Create a free account to save your portfolio and track its performance over time.
More stocks to practice
Designs the iPhone, Mac, and a huge services ecosystem.
Windows, Office, Azure cloud, and enterprise software.
The leading designer of AI and gaming GPUs.
E-commerce giant and the largest cloud provider (AWS).
Google Search, YouTube, Android, and cloud.
Facebook, Instagram, WhatsApp, and the metaverse.
Compare REGN with peers